Viridian Therapeutics, Inc.
VRDN
$30.43
-$1.02-3.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 23,340.07% | 5.90% | 4.86% | -3.82% | -12.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23,340.07% | 5.90% | 4.86% | -3.82% | -12.97% |
| Cost of Revenue | 46.90% | 77.14% | 154.70% | 64.79% | 36.97% |
| Gross Profit | -5.59% | -77.29% | -155.24% | -64.96% | -37.10% |
| SG&A Expenses | -1.61% | -20.81% | -28.38% | -35.70% | 9.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.79% | 48.12% | 41.63% | 17.50% | 21.93% |
| Operating Income | -15.93% | -48.17% | -41.67% | -17.52% | -21.98% |
| Income Before Tax | -17.46% | -50.87% | -41.35% | -13.55% | -18.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.46% | -50.87% | -41.35% | -13.55% | -18.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.46% | -50.87% | -41.35% | -13.55% | -18.66% |
| EBIT | -15.93% | -48.17% | -41.67% | -17.52% | -21.98% |
| EBITDA | -15.99% | -48.31% | -41.79% | -17.55% | -21.98% |
| EPS Basic | -4.85% | -17.56% | 9.29% | 38.94% | 54.30% |
| Normalized Basic EPS | 13.70% | -4.88% | 5.88% | 25.50% | 15.42% |
| EPS Diluted | -4.85% | -17.56% | 9.29% | 38.94% | 54.30% |
| Normalized Diluted EPS | 13.70% | -4.88% | 5.88% | 25.50% | 15.42% |
| Average Basic Shares Outstanding | 34.73% | 41.74% | 47.54% | 51.78% | 42.05% |
| Average Diluted Shares Outstanding | 34.73% | 41.74% | 47.54% | 51.78% | 42.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |